---
document_datetime: 2025-12-02 04:57:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/copalia-hct.html
document_name: copalia-hct.html
version: success
processing_time: 0.1612143
conversion_datetime: 2025-12-24 20:28:17.716408
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Copalia HCT

[RSS](/en/individual-human-medicine.xml/66952)

##### Authorised

This medicine is authorised for use in the European Union

amlodipine / valsartan / hydrochlorothiazide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Copalia HCT](#news-on)
- [More information on Copalia HCT](#more-information-on-copalia-hct-832)
- [More information on Copalia HCT](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Copalia HCT. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Copalia HCT.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Copalia HCT?

Copalia HCT is a medicine that contains three active substances, amlodipine, valsartan and hydrochlorothiazide. It is available as tablets containing amlodipine, valsartan and hydrochlorothiazide in the following amounts: 5/160/12.5 mg, 10/160/12.5 mg, 5/160/25 mg; 10/160/25 mg and 10/320/25 mg.

## What is Copalia HCT used for?

Copalia HCT is used to treat essential hypertension (high blood pressure) in adults whose blood pressure is already adequately controlled with a combination of amlodipine, valsartan and hydrochlorothiazide. 'Essential' means that the hypertension has no obvious cause.

The medicine can only be obtained with a prescription.

## How is Copalia HCT used?

Copalia HCT is taken by mouth as one tablet once a day, at the same time of the day and preferably in the morning. The dose of Copalia HCT to be used is the same as the doses of three individual active substances that the patient was taking before. The daily dose of Copalia HCT should not exceed 10 mg of amlodipine, 320 mg of valsartan and 25 mg of hydrochlorothiazide.

## How does Copalia HCT work?

The three active substances in Copalia HCT are antihypertensive medicines that are already in use in the European Union (EU).

Amlodipine is a 'calcium-channel blocker'. It blocks special channels on the surface of cells called calcium channels, through which calcium ions normally enter the cells. When calcium ions enter the cells in the muscles of blood-vessel walls, this causes contraction. By reducing the flow of calcium into the cells, amlodipine prevents the cells from contracting and helps the blood-vessel walls to relax and widen, thereby reducing blood pressure.

Valsartan is an 'angiotensin-II-receptor antagonist', which means that it blocks the action of a body hormone called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, valsartan stops the hormone having an effect, allowing the blood vessels to widen and blood pressure to reduce. Hydrochlorothiazide is a diuretic. It works by increasing urine output, reducing the volume of fluid in the blood and lowering the blood pressure.

The combination of the three active substances has an additive effect, reducing the blood pressure more than the individual medicines alone. By lowering the blood pressure, the risks associated with high blood pressure, such as having a stroke, are reduced.

## How has Copalia HCT been studied?

Because the combination of the three active substances has been in use for a number of years, the company presented studies showing that the tablet containing all three substances is absorbed in the body in the same way as the separate tablets.

In addition, one main study was carried out in 2,271 patients with moderate to severe hypertension with the highest strength of Copalia HCT (320 mg valsartan, 10 mg amlodipine and 25 mg hydrochlorothiazide). Patients received either Copalia HCT or one of the three combinations containing only two of the active substances for eight weeks. The main measure of effectiveness was the average change in the blood pressure.

## What benefit has Copalia HCT shown during the studies?

Treatment with the highest strength of Copalia HCT was more effective at treating hypertension than dual combinations containing any of the two active substances. The average reduction in blood pressure was around 39.7/24.7 mmHg in patients taking Copalia HCT compared with 32/19.7 mmHg, 33.5/21.5 mmHg and 31.5/19.5 mmHg in patients taking valsartan/hydrochlorothiazide, valsartan/amlodipine and hydrochlorothiazide/amlodipine combinations, respectively.

## What is the risk associated with Copalia HCT?

The most common side effects with Copalia HCT (seen in between 1 and 10 patients in 100) are hypokalaemia (low blood potassium levels), dizziness, headache, hypotension (low blood pressure), dyspepsia (heartburn), pollakiuria (abnormally frequent urination), fatigue (tiredness) and oedema (fluid retention). For the full list of all side effects reported with Copalia HCT, see the package leaflet.

Copalia HCT must not be used in people who are hypersensitive (allergic) to the active substances, to other sulfonamides, to dihydropyridine derivatives or to any of the other ingredients in Copalia HCT. It must not be used in women who are more than three months pregnant. It must also not be used in patients who have liver or bile problems (such as jaundice), severe kidney problems, anuria (a condition in which a patient cannot make or pass urine) or in patients undergoing dialysis (a blood clearance technique). Finally, Copalia HCT must not be used in patients with hypokalaemia (low blood potassium levels), hyponatraemia (low blood sodium levels) and hypercalcaemia (high blood calcium levels) that do not respond to treatment and in patients with hyperuricaemia (high blood levels of uric acid) that causes symptoms.

Copalia HCT must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension) in patients with type 2 diabetes or in patients with moderate or severe kidney impairment.

## Why has Copalia HCT been approved?

The CHMP noted that patients already taking the three active substances would be more likely to comply with their treatment if prescribed Copalia HCT which combines the three substances in a single tablet. The main study showed the benefit of the highest strength of Copalia HCT in lowering the blood pressure. For all doses, Copalia HCT also met requirements to prove that it was comparable to the combinations of the individual active substances taken separately. The CHMP therefore decided that Copalia HCT's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Copalia HCT

The European Commission granted a marketing authorisation valid throughout the European Union for Copalia HCT on 4 November 2009.

Copalia HCT : EPAR - Summary for the public

English (EN) (76.24 KB - PDF)

**First published:** 18/11/2009

**Last updated:** 13/12/2013

[View](/en/documents/overview/copalia-hct-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-928)

български (BG) (103.72 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/bg/documents/overview/copalia-hct-epar-summary-public_bg.pdf)

español (ES) (76.91 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/es/documents/overview/copalia-hct-epar-summary-public_es.pdf)

čeština (CS) (125 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/cs/documents/overview/copalia-hct-epar-summary-public_cs.pdf)

dansk (DA) (98.46 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/da/documents/overview/copalia-hct-epar-summary-public_da.pdf)

Deutsch (DE) (77.72 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/de/documents/overview/copalia-hct-epar-summary-public_de.pdf)

eesti keel (ET) (75.69 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/et/documents/overview/copalia-hct-epar-summary-public_et.pdf)

ελληνικά (EL) (102.83 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/el/documents/overview/copalia-hct-epar-summary-public_el.pdf)

français (FR) (77.79 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/fr/documents/overview/copalia-hct-epar-summary-public_fr.pdf)

hrvatski (HR) (70.78 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/hr/documents/overview/copalia-hct-epar-summary-public_hr.pdf)

italiano (IT) (100.64 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/it/documents/overview/copalia-hct-epar-summary-public_it.pdf)

latviešu valoda (LV) (98.98 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/lv/documents/overview/copalia-hct-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (98.82 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/lt/documents/overview/copalia-hct-epar-summary-public_lt.pdf)

magyar (HU) (96.04 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/hu/documents/overview/copalia-hct-epar-summary-public_hu.pdf)

Malti (MT) (103.53 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/mt/documents/overview/copalia-hct-epar-summary-public_mt.pdf)

Nederlands (NL) (76.51 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/nl/documents/overview/copalia-hct-epar-summary-public_nl.pdf)

polski (PL) (103.2 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/pl/documents/overview/copalia-hct-epar-summary-public_pl.pdf)

português (PT) (99.35 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/pt/documents/overview/copalia-hct-epar-summary-public_pt.pdf)

română (RO) (98.57 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/ro/documents/overview/copalia-hct-epar-summary-public_ro.pdf)

slovenčina (SK) (123.39 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/sk/documents/overview/copalia-hct-epar-summary-public_sk.pdf)

slovenščina (SL) (92.17 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/sl/documents/overview/copalia-hct-epar-summary-public_sl.pdf)

Suomi (FI) (75.89 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/fi/documents/overview/copalia-hct-epar-summary-public_fi.pdf)

svenska (SV) (99.46 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

13/12/2013

[View](/sv/documents/overview/copalia-hct-epar-summary-public_sv.pdf)

## Product information

Copalia HCT : EPAR - Product Information

English (EN) (488.63 KB - PDF)

**First published:** 17/11/2009

**Last updated:** 12/02/2025

[View](/en/documents/product-information/copalia-hct-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-239)

български (BG) (690.32 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/bg/documents/product-information/copalia-hct-epar-product-information_bg.pdf)

español (ES) (547.31 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/es/documents/product-information/copalia-hct-epar-product-information_es.pdf)

čeština (CS) (556.68 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/cs/documents/product-information/copalia-hct-epar-product-information_cs.pdf)

dansk (DA) (527.56 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/da/documents/product-information/copalia-hct-epar-product-information_da.pdf)

Deutsch (DE) (462.33 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/de/documents/product-information/copalia-hct-epar-product-information_de.pdf)

eesti keel (ET) (505.75 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/et/documents/product-information/copalia-hct-epar-product-information_et.pdf)

ελληνικά (EL) (594.51 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/el/documents/product-information/copalia-hct-epar-product-information_el.pdf)

français (FR) (661.79 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/fr/documents/product-information/copalia-hct-epar-product-information_fr.pdf)

hrvatski (HR) (623.49 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/hr/documents/product-information/copalia-hct-epar-product-information_hr.pdf)

íslenska (IS) (510.54 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/is/documents/product-information/copalia-hct-epar-product-information_is.pdf)

italiano (IT) (532.58 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/it/documents/product-information/copalia-hct-epar-product-information_it.pdf)

latviešu valoda (LV) (633.09 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/lv/documents/product-information/copalia-hct-epar-product-information_lv.pdf)

lietuvių kalba (LT) (647.21 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/lt/documents/product-information/copalia-hct-epar-product-information_lt.pdf)

magyar (HU) (566.39 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/hu/documents/product-information/copalia-hct-epar-product-information_hu.pdf)

Malti (MT) (726.54 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/mt/documents/product-information/copalia-hct-epar-product-information_mt.pdf)

Nederlands (NL) (504.13 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/nl/documents/product-information/copalia-hct-epar-product-information_nl.pdf)

norsk (NO) (590.32 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/no/documents/product-information/copalia-hct-epar-product-information_no.pdf)

polski (PL) (732.5 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/pl/documents/product-information/copalia-hct-epar-product-information_pl.pdf)

português (PT) (617.6 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/pt/documents/product-information/copalia-hct-epar-product-information_pt.pdf)

română (RO) (557.65 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/ro/documents/product-information/copalia-hct-epar-product-information_ro.pdf)

slovenčina (SK) (675.71 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/sk/documents/product-information/copalia-hct-epar-product-information_sk.pdf)

slovenščina (SL) (540.94 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/sl/documents/product-information/copalia-hct-epar-product-information_sl.pdf)

Suomi (FI) (505.79 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/fi/documents/product-information/copalia-hct-epar-product-information_fi.pdf)

svenska (SV) (578.35 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

12/02/2025

[View](/sv/documents/product-information/copalia-hct-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000246587 11/02/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Copalia HCT : EPAR - All Authorised presentations

English (EN) (13.82 KB - PDF)

**First published:** 18/11/2009

**Last updated:** 18/11/2009

[View](/en/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-260)

български (BG) (84.29 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/bg/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_bg.pdf)

español (ES) (16.36 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/es/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_es.pdf)

čeština (CS) (81.33 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/cs/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (16.63 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/da/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (16.51 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/de/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.36 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/et/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (83.22 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/el/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_el.pdf)

français (FR) (17.24 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/fr/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (68.96 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/hr/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (44.54 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/is/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_is.pdf)

italiano (IT) (16.61 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/it/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (84.13 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/lv/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (84.53 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/lt/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (86.47 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/hu/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (81.08 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/mt/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (15.36 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/nl/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (48.69 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/no/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_no.pdf)

polski (PL) (47.66 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/pl/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_pl.pdf)

português (PT) (15.24 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/pt/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_pt.pdf)

română (RO) (80.89 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/ro/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (80.28 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/sk/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (15.19 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/sl/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.34 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/fi/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (14.66 KB - PDF)

**First published:**

18/11/2009

**Last updated:**

18/11/2009

[View](/sv/documents/all-authorised-presentations/copalia-hct-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Copalia HCT Active substance

- amlodipine
- valsartan
- hydrochlorothiazide

International non-proprietary name (INN) or common name

- amlodipine
- valsartan
- hydrochlorothiazide

Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09DX01

### Pharmacotherapeutic group

- Agents acting on the renin-angiotensin system
- Angiotensin II antagonists and calcium channel blockers
- Angiotensin II antagonists, combinations

### Therapeutic indication

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.

## Authorisation details

EMA product number EMEA/H/C/001159 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Marketing authorisation issued 03/11/2009 Revision 27

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Copalia HCT : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (142.3 KB - PDF)

**First published:** 12/02/2025

[View](/en/documents/procedural-steps-after/copalia-hct-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Copalia HCT : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (6.39 MB - PDF)

**First published:** 26/08/2010

**Last updated:** 12/02/2025

[View](/en/documents/procedural-steps-after/copalia-hct-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Angiotensin-II-receptor antagonists (sartans) : Scientific conclusions - Impact of the Article 5(3) scientific opinion on nitrosamines

Adopted

English (EN) (119.28 KB - PDF)

**First published:** 05/07/2021

[View](/en/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_en.pdf)

[Other languages (22)](#file-language-dropdown-113)

български (BG) (145.18 KB - PDF)

**First published:**

05/07/2021

[View](/bg/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_bg.pdf)

español (ES) (125.85 KB - PDF)

**First published:**

05/07/2021

[View](/es/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_es.pdf)

čeština (CS) (139.02 KB - PDF)

**First published:**

05/07/2021

[View](/cs/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_cs.pdf)

dansk (DA) (126.81 KB - PDF)

**First published:**

05/07/2021

[View](/da/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_da.pdf)

Deutsch (DE) (131.05 KB - PDF)

**First published:**

05/07/2021

[View](/de/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_de.pdf)

eesti keel (ET) (123.85 KB - PDF)

**First published:**

05/07/2021

[View](/et/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_et.pdf)

ελληνικά (EL) (139.5 KB - PDF)

**First published:**

05/07/2021

[View](/el/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_el.pdf)

français (FR) (127.12 KB - PDF)

**First published:**

05/07/2021

[View](/fr/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_fr.pdf)

hrvatski (HR) (142.87 KB - PDF)

**First published:**

05/07/2021

[View](/hr/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_hr.pdf)

italiano (IT) (126.56 KB - PDF)

**First published:**

05/07/2021

[View](/it/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_it.pdf)

latviešu valoda (LV) (147.7 KB - PDF)

**First published:**

05/07/2021

[View](/lv/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_lv.pdf)

lietuvių kalba (LT) (148.34 KB - PDF)

**First published:**

05/07/2021

[View](/lt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_lt.pdf)

magyar (HU) (137.17 KB - PDF)

**First published:**

05/07/2021

[View](/hu/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_hu.pdf)

Malti (MT) (151.21 KB - PDF)

**First published:**

05/07/2021

[View](/mt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_mt.pdf)

Nederlands (NL) (127.53 KB - PDF)

**First published:**

05/07/2021

[View](/nl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_nl.pdf)

polski (PL) (137.7 KB - PDF)

**First published:**

05/07/2021

[View](/pl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_pl.pdf)

português (PT) (128.87 KB - PDF)

**First published:**

05/07/2021

[View](/pt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_pt.pdf)

română (RO) (143.59 KB - PDF)

**First published:**

05/07/2021

[View](/ro/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_ro.pdf)

slovenčina (SK) (135.07 KB - PDF)

**First published:**

05/07/2021

[View](/sk/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sk.pdf)

slovenščina (SL) (149.74 KB - PDF)

**First published:**

05/07/2021

[View](/sl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sl.pdf)

Suomi (FI) (125.84 KB - PDF)

**First published:**

05/07/2021

[View](/fi/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_fi.pdf)

svenska (SV) (126.99 KB - PDF)

**First published:**

05/07/2021

[View](/sv/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sv.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report - Impact of the Article 5(3) scientific opinion on nitrosamines

Adopted

Reference Number: EMA/47245/2021

English (EN) (362.31 KB - PDF)

**First published:** 02/03/2021

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report-impact-article-53-scientific-opinion-nitrosamines_en.pdf)

Copalia HCT : EPAR - Scientific conclusions - Annex IV

English (EN) (99.42 KB - PDF)

**First published:** 23/05/2019

[View](/en/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_en.pdf)

[Other languages (22)](#file-language-dropdown-683)

български (BG) (136.15 KB - PDF)

**First published:**

23/05/2019

[View](/bg/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_bg.pdf)

español (ES) (98.31 KB - PDF)

**First published:**

23/05/2019

[View](/es/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_es.pdf)

čeština (CS) (131.08 KB - PDF)

**First published:**

23/05/2019

[View](/cs/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_cs.pdf)

dansk (DA) (96.12 KB - PDF)

**First published:**

23/05/2019

[View](/da/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_da.pdf)

Deutsch (DE) (100.2 KB - PDF)

**First published:**

23/05/2019

[View](/de/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_de.pdf)

eesti keel (ET) (94.4 KB - PDF)

**First published:**

23/05/2019

[View](/et/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_et.pdf)

ελληνικά (EL) (142.79 KB - PDF)

**First published:**

23/05/2019

[View](/el/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_el.pdf)

français (FR) (97.56 KB - PDF)

**First published:**

23/05/2019

[View](/fr/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_fr.pdf)

hrvatski (HR) (125.02 KB - PDF)

**First published:**

23/05/2019

[View](/hr/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_hr.pdf)

italiano (IT) (95.54 KB - PDF)

**First published:**

23/05/2019

[View](/it/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_it.pdf)

latviešu valoda (LV) (130.68 KB - PDF)

**First published:**

23/05/2019

[View](/lv/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_lv.pdf)

lietuvių kalba (LT) (130.84 KB - PDF)

**First published:**

23/05/2019

[View](/lt/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_lt.pdf)

magyar (HU) (119.82 KB - PDF)

**First published:**

23/05/2019

[View](/hu/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_hu.pdf)

Malti (MT) (133.78 KB - PDF)

**First published:**

23/05/2019

[View](/mt/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_mt.pdf)

Nederlands (NL) (99.3 KB - PDF)

**First published:**

23/05/2019

[View](/nl/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_nl.pdf)

polski (PL) (130.65 KB - PDF)

**First published:**

23/05/2019

[View](/pl/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_pl.pdf)

português (PT) (96.47 KB - PDF)

**First published:**

23/05/2019

[View](/pt/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_pt.pdf)

română (RO) (128.25 KB - PDF)

**First published:**

23/05/2019

[View](/ro/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_ro.pdf)

slovenčina (SK) (119.14 KB - PDF)

**First published:**

23/05/2019

[View](/sk/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_sk.pdf)

slovenščina (SL) (124.14 KB - PDF)

**First published:**

23/05/2019

[View](/sl/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_sl.pdf)

Suomi (FI) (97.12 KB - PDF)

**First published:**

23/05/2019

[View](/fi/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_fi.pdf)

svenska (SV) (96.85 KB - PDF)

**First published:**

23/05/2019

[View](/sv/documents/scientific-conclusion/copalia-hct-epar-scientific-conclusions-annex-iv_sv.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report

Adopted

Reference Number: EMA/217823/2019

English (EN) (531.32 KB - PDF)

**First published:** 02/05/2019

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report_en.pdf)

Copalia HCT-H-C-1159-A31-30 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/PRAC/294920/2014

English (EN) (301.42 KB - PDF)

**First published:** 01/10/2014

**Last updated:** 01/10/2014

[View](/en/documents/variation-report/copalia-hct-h-c-1159-a31-30-epar-assessment-report-article-31_en.pdf)

Copalia HCT-H-C-1159-A31-30: EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommen...

English (EN) (48.81 KB - PDF)

**First published:** 01/10/2014

**Last updated:** 01/10/2014

[View](/en/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_en.pdf)

[Other languages (22)](#file-language-dropdown-75)

български (BG) (87.49 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/bg/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_bg.pdf)

español (ES) (50.51 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/es/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_es.pdf)

čeština (CS) (82.81 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/cs/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_cs.pdf)

dansk (DA) (49.01 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/da/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_da.pdf)

Deutsch (DE) (53.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/de/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_de.pdf)

eesti keel (ET) (50.6 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/et/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_et.pdf)

ελληνικά (EL) (89.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/el/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_el.pdf)

français (FR) (51.91 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/fr/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_fr.pdf)

hrvatski (HR) (80.12 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/hr/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_hr.pdf)

italiano (IT) (51.13 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/it/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_it.pdf)

latviešu valoda (LV) (81.63 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/lv/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_lv.pdf)

lietuvių kalba (LT) (82.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/lt/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_lt.pdf)

magyar (HU) (68.7 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/hu/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_hu.pdf)

Malti (MT) (84.23 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/mt/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_mt.pdf)

Nederlands (NL) (49.82 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/nl/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_nl.pdf)

polski (PL) (83.62 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/pl/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_pl.pdf)

português (PT) (49.74 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/pt/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_pt.pdf)

română (RO) (88.19 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/ro/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_ro.pdf)

slovenčina (SK) (81.5 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sk/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_sk.pdf)

slovenščina (SL) (79.79 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sl/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_sl.pdf)

Suomi (FI) (49.15 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/fi/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_fi.pdf)

svenska (SV) (50.18 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sv/documents/scientific-conclusion/copalia-hct-h-c-1159-a31-30-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommen_sv.pdf)

Copalia HCT-H-C-1160-WS-359 : EPAR - Assessment Report - Variation

English (EN) (446.67 KB - PDF)

**First published:** 12/12/2013

**Last updated:** 12/12/2013

[View](/en/documents/variation-report/copalia-hct-h-c-1160-ws-359-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Copalia HCT

Adopted

Reference Number: EMA/CHMP/397231/2013

English (EN) (68.37 KB - PDF)

**First published:** 28/06/2013

**Last updated:** 28/06/2013

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-copalia-hct_en.pdf)

## Initial marketing authorisation documents

Copalia HCT : EPAR - Public assessment report

English (EN) (1.23 MB - PDF)

**First published:** 18/11/2009

**Last updated:** 18/11/2009

[View](/en/documents/assessment-report/copalia-hct-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use summary of positive opinion for Copalia HCT

Reference Number: EMEA/CHMP/471503/2009

English (EN) (34.22 KB - PDF)

**First published:** 23/07/2009

**Last updated:** 23/07/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-copalia-hct_en.pdf)

#### News on Copalia HCT

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2013) 28/06/2013

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-october-2011) 21/10/2011

[European Medicines Agency concludes that benefit-risk balance of angiotensin-II-receptor antagonists remains positive](/en/news/european-medicines-agency-concludes-benefit-risk-balance-angiotensin-ii-receptor-antagonists-remains-positive) 20/10/2011

#### More information on Copalia HCT

- [Valsartan containing medicinal products: Article 31 referrals](/en/medicines/human/referrals/sartan-medicines)
- [Renin-angiotensin-system (RAS)-acting agents: Article-31 referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

Questions and answers on the review of angiotensin-II-receptor antagonists and the risk of cancer

Reference Number: EMA/CHMP/834168/2011

English (EN) (511.41 KB - PDF)

**First published:** 20/10/2011

**Last updated:** 11/05/2017

[View](/en/documents/opinion-any-scientific-matter/questions-answers-review-angiotensin-ii-receptor-antagonists-risk-cancer_en.pdf)

#### More information on Copalia HCT

- [EMEA-000397-PIP01-08 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000397-pip01-08)
- [Renin-angiotensin-system (RAS)-acting agents - referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)
- [Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group - referral](/en/medicines/human/referrals/angiotensin-ii-receptor-antagonists-sartans-containing-tetrazole-group)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 12/02/2025

## Share this page

[Back to top](#main-content)